Tumorgrafts as in vivo surrogates for women with ovarian cancer

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1288-1297

  Weroha, S John ^a   Becker, Marc A ^a   Enderica Gonzalez, Sergio ^a   Harrington, Sean C ^a   Oberg, Ann L ^b   Maurer, Matthew J ^b   Perkins, Sarah E ^b   AlHilli, Mariam ^d   Butler, Kristina A ^d   McKinstry, Sarah ^a   Fink, Stephanie ^a   Jenkins, Robert B ^a   Hou, Xiaonan ^a   Kalli, Kimberly R ^a   Goodman, Karin M ^a   Sarkaria, Jann N ^b   Karlan, Beth Y ^e   Kumar, Amanika ^d   Kaufmann, Scott H ^a,c   Hartmann, Lynn C ^a   Haluska, Paul ^a   more..

^a MAYO CLINIC   (United States)

^b Radiation Oncology ^*  (United States)

^c Molecular Pharmacology and Experimental Therapeutics   (United States)

^d Division of Gynecologic Surgery   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRAFT; CANCER MODEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HEALTH CARE FACILITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SCID MOUSE; TUMOR BANK; TUMOR ENGRAFTMENT; UTERINE TUBE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT SURVIVAL; HETEROGRAFTS; HUMANS; MICE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895814753     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2611     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
3. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-7.
4. Hausser HJ, Brenner RE. Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun 2005;333: 216-22.
5. Wenger SL, Senft JR, Sargent LM, Bamezai R, Bairwa N, Grant SG. Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization. Biosci Rep 2004; 24:631-9.
6. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013;4:2126.
7. Karam AK, Chiang JW, Fung E, Nossov V, Karlan BY. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol 2009;114:246-52.
8. Langdon SP, Hendriks HR, Braakhuis BJ, Pratesi G, Berger DP, Fodstad O, et al. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol 1994; 5:415-22.
9. Ward BG, Wallace K, Shepherd JH, Balkwill FR. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res 1987;47:2662-7.
10. Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 1989;44:494-500.
11. Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ Jr., Barnas JL, et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS ONE 2011;6:e24420.
12. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D, Karlan BY. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 2002;87:200-6.
13. Xu Y, Silver DF, Yang NP, Oflazoglu E, Hempling RE, Piver MS, et al. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol 1999;72:161-70.
14. Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol 2008;110:256-64.
15. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10:1311-6.
16. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patientderived ovarian cancer tissue xenografts. Clin Cancer Res 2011; 17:783-91.
17. Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, et al. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res 2011;17: 4451-61.
18. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 2009;69:8987-95.
19. Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol 2012;14:870-81.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4:249-64.
21. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003;31:265-73.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci US A 1998;95:14863-8.
23. Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004;20:3246-8.
24. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013;123:517-25.
25. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-5.
26. Staflin K, Jarnum S, Hua J, Honeth G, Kannisto P, Lindvall M. Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma. Int J Gynecol Cancer 2006;16:1557-64.
27. Barda G, Menczer J, Chetrit A, Lubin F, Beck D, Piura B, et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 2004;190: 1039-45.
28. Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 2001;11:403-8.
29. Jaaback KS, Ludeman L, Clayton NL, Hirschowitz L. Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. Int J Gynecol Cancer 2006;16 Suppl 1:123-8.
30. Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993;51:171-4.
31. Custer RP, Bosma GC, Bosma MJ. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. Am J Pathol 1985;120:464-77.
32. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192-8.
33. Papadopulos F, Spinelli M, Valente S, Foroni L, Orrico C, Alviano F, et al. Common tasks in microscopic and ultrastructural image analysis using ImageJ. Ultrastruct Pathol 2007;31:401-7.
34. Bohn W, Wiegers W, Beuttenmuller M, Traub P. Species-specific recognition patterns of monoclonal antibodies directed against vimentin. Exp Cell Res 1992;201:1-7.
35. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
36. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
37. van der Burg ME, Vergote I, Onstenk W, Boere IA, Leunen K, van Montfort CA, et al. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer. Eur J Cancer 2013;49: 1254-63.
38. Harrap KR, Jones M, Siracky J, Pollard LA, Kelland LR. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann Oncol 1990;1:65-76.
39. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005; 96:48-55.
40. Epiney M, Bertossa C, Weil A, Campana A, Bischof P. CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000;15:1261-5.
41. Goodell CA, Belisle JA, Gubbels JA, Migneault M, Rancourt C, Connor J, et al. Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of crossreactive monoclonal antibodies. J Ovarian Res 2009;2:8.